Leqvio FDA Approval

LeqvioⓇ provides an innovative and differentiated approach to lowering LDL-C in ACSVD patients First and only siRNA LDL cholesterol lowering treatment4,5 Effective and sustained³ LDL-C reduction¹ ORION-10 Percentage change in LDL Twice-yearly dosing 1.2 Dosing scheme³ every 6 months 20 Inclisiran siRNA Double-stranded Guide strand Passenger strand Percentage change 0 Placebo Initial dose 3 months from baseline -20 -40 -60 Inclisiran -80 May integrate seamlessly into a patient's health care routine -100 0 90 150 270 330 Days 450510540 Triantennary GalNAc conjugate No. of patients Placebo 780 Inclisiran 781 762 745 758 757 724 715 737 731 698 666 670 721 691 705 9 months LDL-C - Low Density Lipoprotein Choletsterol ASCVD Atherosclerotic Cardiovascular Disease siRNA-small interfering Ribonucleic Acid 1. Ray KK, et al. N Engl J Med. 2020;382(16): 1507-1519. 2. After an initial dose, again at 3 months, and again every six months thereafter. As a strong complement to a maximally tolerated statin. 3. LDL-C reduction was maintained during each 6-month dosing interval. 4. Khvorova A, et al. N Engl J Med. 2017;376:4-7 5. Fitzgerald K, et al. N Engl J Med. 2017;376:41-51. 9 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine

View entire presentation